Your browser is no longer supported. Please, upgrade your browser.
Palatin Technologies, Inc.
Index- P/E- EPS (ttm)-0.11 Insider Own3.81% Shs Outstand236.83M Perf Week6.72%
Market Cap141.87M Forward P/E- EPS next Y-0.07 Insider Trans0.00% Shs Float220.39M Perf Month26.45%
Income-27.00M PEG- EPS next Q-0.03 Inst Own11.30% Short Float2.93% Perf Quarter-23.42%
Sales-0.45M P/S- EPS this Y-158.00% Inst Trans-14.31% Short Ratio3.37 Perf Half Y43.50%
Book/sh0.27 P/B2.26 EPS next Y36.40% ROA-30.50% Target Price- Perf Year-1.60%
Cash/sh0.29 P/C2.07 EPS next 5Y- ROE-37.50% 52W Range0.38 - 1.30 Perf YTD-9.74%
Dividend- P/FCF- EPS past 5Y8.10% ROI-29.40% 52W High-53.08% Beta1.40
Dividend %- Quick Ratio7.30 Sales past 5Y-60.90% Gross Margin- 52W Low62.67% ATR0.03
Employees20 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)58.83 Volatility4.79% 5.73%
OptionableNo Debt/Eq0.00 EPS Q/Q-5.80% Profit Margin- Rel Volume0.52 Prev Close0.61
ShortableYes LT Debt/Eq0.00 EarningsMay 17 BMO Payout- Avg Volume1.92M Price0.61
Recom1.30 SMA208.37% SMA504.30% SMA200-0.58% Volume1,014,530 Change0.30%
Jun-05-15Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15Reiterated ROTH Capital Buy $6 → $4
May-23-12Initiated Noble Financial Buy
Jan-23-07Initiated Next Generation Buy $5
Jun-10-21 07:30AM  
May-17-21 09:15AM  
May-14-21 07:30AM  
May-13-21 07:30AM  
May-04-21 07:30AM  
Apr-20-21 07:30AM  
Mar-11-21 08:17AM  
Mar-05-21 07:30AM  
Feb-17-21 09:15AM  
Feb-12-21 07:30AM  
Feb-11-21 09:59AM  
Feb-10-21 08:01AM  
Feb-05-21 09:47AM  
Feb-04-21 11:30AM  
Dec-22-20 01:17PM  
Dec-15-20 07:00AM  
Nov-29-20 12:13PM  
Nov-19-20 11:11AM  
Nov-17-20 09:15AM  
Nov-12-20 07:30AM  
Sep-28-20 09:00AM  
Sep-24-20 04:00PM  
Sep-10-20 05:47PM  
Aug-13-20 04:12PM  
Jul-14-20 01:19PM  
Jul-08-20 07:30AM  
Jun-29-20 07:30AM  
Jun-23-20 04:54PM  
Jun-05-20 03:14PM  
May-14-20 07:02PM  
May-13-20 03:01AM  
May-12-20 07:30AM  
Apr-30-20 07:30AM  
Mar-28-20 10:28AM  
Mar-03-20 12:56PM  
Feb-21-20 10:22AM  
Feb-19-20 07:30AM  
Feb-11-20 07:30AM  
Feb-06-20 07:30AM  
Jan-21-20 07:30AM  
Jan-16-20 08:36AM  
Dec-20-19 05:13PM  
Dec-11-19 11:43AM  
Dec-03-19 11:44PM  
Nov-13-19 07:30AM  
Nov-07-19 07:30AM  
Oct-31-19 11:53AM  
Oct-17-19 07:00AM  
Oct-16-19 07:00AM  
Oct-08-19 02:06PM  
Sep-17-19 05:41PM  
Sep-12-19 07:30AM  
Sep-11-19 12:00PM  
Aug-19-19 10:44AM  
Aug-16-19 10:42AM  
Aug-13-19 05:45PM  
Aug-06-19 09:30AM  
Jul-26-19 05:45PM  
Jul-19-19 05:45PM  
Jul-17-19 09:30AM  
Jul-12-19 12:51PM  
Jul-01-19 07:00AM  
Jun-25-19 03:49PM  
Jun-24-19 04:45PM  
Jun-21-19 05:41PM  
Jun-06-19 07:30AM  
May-20-19 03:48PM  
May-14-19 08:17AM  
May-10-19 01:23PM  
May-09-19 09:00AM  
May-03-19 04:30PM  
Apr-15-19 09:27AM  
Apr-05-19 10:46AM  
Apr-04-19 07:30AM  
Mar-02-19 08:34AM  
Feb-26-19 07:40AM  
Feb-12-19 05:20PM  
Feb-06-19 07:30AM  
Dec-30-18 03:27PM  
Dec-18-18 12:06PM  
Dec-07-18 02:20PM  
Nov-27-18 07:40AM  
Nov-17-18 08:08AM  
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEVEER ROBERT K JRDirectorNov 18Buy0.4154,00022,140728,638Nov 30 09:35 PM
DEVEER ROBERT K JRDirectorSep 29Sale0.4654,00024,980643,472Oct 02 04:15 PM